Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELICE-BD
2019-002213-19Phase 3Unknown
- Sponsor
- University of British Columbia
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Latuda adjunctive therapy with Placebo add-on (2 arms). Primary endpoints: Change in composite cognitive score and Change in functioning. Status: unknown.
02
Drugs
lurasidone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2019-002213-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002213-19.